Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-05-19
2010-10-05
Szperka, Michael (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S141100, C424S145100, C530S387300, C530S388250, C435S070100, C435S328000
Reexamination Certificate
active
07807162
ABSTRACT:
The present invention relates to improved Nanobodies™ against von Willebrand Factor (vWF), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.
REFERENCES:
patent: 5238919 (1993-08-01), Zimmerman et al.
patent: 5670132 (1997-09-01), Griffiths et al.
patent: 5916805 (1999-06-01), Nagano et al.
patent: 5976532 (1999-11-01), Coller et al.
patent: 6228360 (2001-05-01), Co et al.
patent: 6251393 (2001-06-01), Handin et al.
patent: 6280731 (2001-08-01), Nagano et al.
patent: 6419934 (2002-07-01), Tobinick
patent: 6517829 (2003-02-01), Frenken et al.
patent: 6759518 (2004-07-01), Kontermann et al.
patent: 6793920 (2004-09-01), Nagano et al.
patent: 7311913 (2007-12-01), Co et al.
patent: 2001/0024647 (2001-09-01), Handin et al.
patent: 2002/0028204 (2002-03-01), Nagano et al.
patent: 2002/0058033 (2002-05-01), Raisch et al.
patent: 2003/0092892 (2003-05-01), Frenken et al.
patent: 2005/0136056 (2005-06-01), Kageyama et al.
patent: 2005/0192224 (2005-09-01), Huizinga et al.
patent: 2006/0149041 (2006-07-01), Silence
patent: 2006/0286066 (2006-12-01), Basran
patent: 2008/0096223 (2008-04-01), De Groot et al.
patent: 0 295 645 (1988-12-01), None
patent: 0 368 684 (1994-03-01), None
patent: 0 952 218 (1999-10-01), None
patent: 1 002 861 (2000-05-01), None
patent: 03447005.4 (2003-01-01), None
patent: WO 90/10707 (1990-09-01), None
patent: WO 93/11161 (1993-06-01), None
patent: WO 94/04678 (1994-03-01), None
patent: WO 94/13806 (1994-06-01), None
patent: WO 94/25591 (1994-11-01), None
patent: WO 96/17078 (1996-06-01), None
patent: WO 97/38102 (1997-10-01), None
patent: WO 99/09055 (1999-02-01), None
patent: WO 99/23221 (1999-05-01), None
patent: WO 00/24781 (2000-05-01), None
patent: WO 01/02853 (2001-01-01), None
patent: WO 02/051351 (2002-07-01), None
patent: WO 02/057445 (2002-07-01), None
patent: PCT/EP03/06581 (2003-06-01), None
patent: PCT/EP03/07313 (2003-07-01), None
patent: PCT/BE03/00191 (2003-12-01), None
patent: PCT/BE03/00206 (2003-12-01), None
patent: WO 2004/003019 (2004-01-01), None
patent: WO 2004/015425 (2004-02-01), None
patent: WO 2004/041862 (2004-05-01), None
patent: WO 2004/041863 (2004-05-01), None
patent: WO 2004/041865 (2004-05-01), None
patent: WO 2004/041867 (2004-05-01), None
patent: WO 2004/062551 (2004-07-01), None
patent: WO 2004/062551 (2004-07-01), None
patent: WO 2005/044858 (2005-05-01), None
patent: WO 2006/074947 (2006-07-01), None
patent: WO 2006/122825 (2006-11-01), None
patent: WO 2008/049881 (2008-05-01), None
Varga-Szabo et al., Arterioscler Thromb Vasc Biol. Mar. 2008;28(3):403-12. Epub Jan. 3, 2008. Review.
Badreldin et al., Interact Cardiovasc Thorac Surg. May 2010;10(5):766-9. Epub Feb. 12, 2010.
Merck Manual of Diagnosis and Therapy, 17thedition, 1999, Beers and Berkow, editors, Merck Reasrch Laboratories, pp. 2057 and 2058.
Wikipedia entry for “embolism” retrieved Apr. 19, 2010.
D'Haens, G. et al. “Endoscopic and Histological Healing With Infliximab Anti-Tumor Necrosis Factor Antibodies in Crohn's Disease: A European Multicenter Trial,”Gastroenterology1999; 116(5):1029-1034.
Hoogenboom, H.R. “Mix and match: Building manifold binding sites,”Nature BiotechnologyFeb. 1999; 15:125-126.
Holliger, P. et al. “Retargeting serum immunoglobulin with bispecific diabodies,”Nature BiotechnologyJul. 1997; 15:632-636.
Ill, C.R. et al., “Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions,”Protein Engineering1997; 10(8):949-957.
Neri, D. et al. “High-affinity Antigen Binding by Chelating Recombinant Antibodies (CRAbs),”J. Mol. Biol. 1995; 246:367-373.
Tanha, J. et al., “Selection by phage display of llama conventional VHfragments with heavy chain antibody VHH properties,”Journal of Immunological Methods2002; 263:97-109.
Valle, E. et al.,Expert Opin. Pharmacother. 2001; 2(6):1015-1025.
Vincke et al. General Strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem 284: 3273-3284, 2009.
[No Author Listed] The Merck Manual of Diagnosis and Therapy, 17thEd. Beers et al, Editors. Merck Research Laboratories, 1999:926-7.
[No Author Listed] Von Willebrand disease. www.wikipedia.org. Accessed Dec. 30, 2008.
Berndt et al., The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost. Jul. 2001;86(1):178-88. Review.
Blanco et al., Formation and stability of beta-hairpin structures in polypeptides. Curr Opin Struct Biol. Feb. 1998;8(1):107-11. Review.
Bonnefoy et al., Shielding the front-strand beta 3 of the von Willebrand factor A1 domain inhibits its binding to platelet glycoprotein Ibalpha. Blood. Feb. 15, 2003;101(4):1375-83. Epub Oct. 10, 2002.
Celikel et al., von Willebrand factor conformation and adhesive function is modulated by an internalized water molecule. Nat Struct Biol. Oct. 2000;7(10):881-4.
Celikel et al., Crystal structure of the von Willebrand factor A1 domain in complex with the function blocking NMC-4 Fab. Nat Struct Biol. Mar. 1998;5(3):189-94.
Chand et al., A two-site, monoclonal antibody-based immunoassay for von Willebrand factor—demonstration that vWF function resides in a conformational epitope. Thromb Haemost. Jun. 30, 1986;55(3):318-24.
Christophe et al., A monoclonal antibody (B724) to von Willebrand factor recognizing an epitope within the A1 disulphide loop (Cys509-Cys695) discriminates between type 2A and type 2B von Willebrand disease. Br J Haematol. May 1995;90(1):195-203.
Conrath et al., Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem. Mar. 9, 2001;276(10):7346-50. Epub Oct. 25, 2000.
Cruz et al., Mapping the glycoprotein Ib-binding site in the von willebrand factor A1 domain. J Biol Chem. Jun. 23, 2000;275(25):19098-105.
De Mast et al., Thrombocytopenia and release of activated von willebrand factor during earlyPlasmodium falciparummalaria . J. Inf. Diseases 2007; 196: 622-628.
Dong et al., Novel gain-of-function mutations of platelet glycoprotein Ibalpha by valine mutagenesis in the Cys209-Cys248 disulfide loop. Functional analysis under statis and dynamic conditions. J Biol Chem. Sep. 8, 2000;275(36):27663-70.
Dong et al., Tyrosine sulfation of glycoprotein I(b)alpha. Role of electrostatic interactions in von Willebrand factor binding. J Biol Chem. May 18, 2001;276(20):16690-4. Epub Feb. 23, 2001.
Els-Conrath et al., Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem. Mar. 9, 2001;276(10):7346-50. Epub Oct. 25, 2000.
Emsley et al., Crystal structure of the von Willebrand Factor A1 domain and implications for the binding of platelet glycoprotein Ib. J Biol Chem. Apr. 24, 1998;273(17):10396-401.
Favaloro et al., Discrimination of von Willebrands disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems. Thromb Haemost. Oct. 2000;84(4):541-7.
Favaloro, Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects. Direct comparison of commercial ELISA-based von Willebrand factor activity options. Am J Clin Pathol. Oct. 2000;114(4):608-18.
Favaloro et al., Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's dis
Ablynx N.V.
Szperka Michael
Wolf Greenfield & Sacks P.C.
LandOfFree
Single domain VHH antibodies against von Willebrand factor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Single domain VHH antibodies against von Willebrand factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Single domain VHH antibodies against von Willebrand factor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4176257